A bill winding its way through the Texas Senate would strictly regulate lawyer advertising for prescription medication and medical device litigation, and impose a civil penalty for violations under the state’s Deceptive Trade Practices Act.
The Senate State Affairs Committee voted 9-0 to pass a substitute version of Senate Bill 1189 after a public hearing April 4. The bill now heads to the full Senate.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
